<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622450</url>
  </required_header>
  <id_info>
    <org_study_id>Colistin inhalation form</org_study_id>
    <nct_id>NCT03622450</nct_id>
  </id_info>
  <brief_title>The Effect of Colistin Inhalation on Ventilator Associated Pneumonia</brief_title>
  <official_title>The Effect of Colistin Inhalation on the Clinical Outcome of Patients With Ventilator Associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nourhan Hassan Osama Thuraya Mohamed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has been conducted to measure the clinical outcome of early intervention with
      colistin inhalation in patients with ventilator associated pneumonia suspected to have
      multidrug resistant gram -ve bacteria
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2016</start_date>
  <completion_date type="Actual">January 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 6, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Ventilatory status</measure>
    <time_frame>7 to 10 days</time_frame>
    <description>Pf ratio measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of mechanical ventilation</measure>
    <time_frame>35 Days</time_frame>
    <description>Deescalation in the ventilation mode and trials until successful weaning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time till the occurence of sepsis</measure>
    <time_frame>35 Days</time_frame>
    <description>long standing ventilator associated pneumonia with failure of treatment can lead to sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality as an outcome of long stand untreatable ventilator associated pneumonia</measure>
    <time_frame>35 days</time_frame>
    <description>is the mortality due to sepsis of other causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the icu</measure>
    <time_frame>35 days</time_frame>
    <description>How long will the patient stay in the ICU according to failure of weaning and progression of the disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Medication arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin</intervention_name>
    <description>Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.</description>
    <arm_group_label>Medication arm</arm_group_label>
    <other_name>Colomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbapenem + Aminoglycoside/ Quinolone</intervention_name>
    <description>Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>tienam,meropenem,levofloxacin,ciprofloxacin,amikacin,gentamicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years

        Patients presenting with signs of infection 48 hours of intubation

        Exclusion Criteria:

          -  Patients with documented bronchiectasis

        Cystic fibrosis Known allergy to polymyxin. Patients presenting with chest infection or
        signs of infection before intubation.

        Patients with creatinine clearance less than 30ml/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Nourhan Hassan Osama Thuraya Mohamed</investigator_full_name>
    <investigator_title>Clinical pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Number of patients ,statistical data, method,discussion and outcome will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

